- Report
- February 2026
- 392 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 553 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 179 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 166 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 390 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 220 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 245 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 373 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 244 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 324 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 184 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 193 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 246 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 197 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 194 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 194 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 273 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- May 2025
- 110 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- May 2025
- 120 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- October 2025
- 148 Pages
Global
From €3502EUR$3,999USD£3,040GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more